FDA Clearance Tracker · P980040-S176
TECNIS PureSee IOL, Model DEN00V TECNIS PureSee Toric II IOLs, Model DET150, DET225, DET300, DET375
Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 11, 2026
Approved
Time to decision
223 days
Received Jul 31, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P980040-S176
- Device name
- TECNIS PureSee IOL, Model DEN00V TECNIS PureSee Toric II IOLs, Model DET150, DET225, DET300, DET375
- Applicant location
- Irvine, CA
- Received
- Jul 31, 2025
- Decided
- Mar 11, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P980040
Device type
- Device type
- intraocular lens (HQL)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the TECNIS SIMPLICITY Delivery System is used to fold and assist in inserting the TECNIS PureSee IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the TECNIS PureSee IOL provides improved intermediate visual acuity, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only. The TECNIS SIMPLICITY Delivery System is used to fold and assist in inserting the TECNIS PureSee Toric II IOLs, which are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed. The lenses mitigate the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the TECNIS PureSee Toric II IOLs provide improved intermediate visual acuity, while maintaining comparable distance visual acuity. The lenses are intended for capsular bag placement only.
Source documents
Other decisions for Johnson & Johnson Surgical Vision, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K223566 · Decided Apr 14, 2023 · 136 days after receipt
Device type: Ophthalmic Femtosecond Laser (OOE) · Ophthalmology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.